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Background: Nurse led self-help treatments for people with chronic fatigue syndrome/myalgic encephalitis
(CFS/ME) have been shown to be effective in reducing fatigue but their cost-effectiveness is unknown.
Methods: Cost-effectiveness analysis conducted alongside a single blind randomised controlled trial comparing
pragmatic rehabilitation (PR) and supportive listening (SL) delivered by primary care nurses, and treatment as usual
(TAU) delivered by the general practitioner (GP) in North West England. A within trial analysis was conducted
comparing the costs and quality adjusted life years (QALYs) measured within the time frame of the trial. 296
patients aged 18 and over with CFS/ME diagnosed using the Oxford criteria were included in the cost-effectiveness
analysis.
Results: Treatment as usual is less expensive and leads to better patient outcomes compared with Supportive
Listening. Treatment as usual is also less expensive than Pragmatic Rehabilitation. PR was effective at reducing
fatigue in the short term, but the impact of the intervention on QALYs was uncertain. However, based on the
results of this trial, PR is unlikely to be cost-effective in this patient population.
Conclusions: This analysis does not support the introduction of SL. Any benefits generated by PR are unlikely to be
of sufficient magnitude to warrant recommending PR for this patient group on cost-effectiveness grounds alone.
However, dissatisfaction with current treatment options means simply continuing with ‘treatment as usual’ in
primary care is unlikely to be acceptable to patients and practitioners.
Trial registration: The trial registration number is IRCTN74156610
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Chronic fatigue syndrome (or myalgic encephalomyelitis /
encephalitis or ME; hereafter abbreviated to CFS/ME)
is characterised by a principal complaint of fatigue, of suf-
ficient duration and severity to impair functioning [1].
CFS/ME causes substantial disability [2], and is associated
with high levels of resource use [3]. The NICE guideline
for CFS/ME [4] emphasises the importance of confident
diagnosis, of starting treatment early, and of developing
tailored care-packages, agreed with the patient, which may
include input from both NHS and social care services. In* Correspondence: richard.morriss@nottingham.ac.uk
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distribution, and reproduction in any mediumthe absence of a clear explanatory model for CFS/ME and
available treatment options, GPs avoid making the diagno-
sis feeling they have nothing to offer patients [5] and there
is still some scepticism about the existence of the condi-
tion. Practice Nurses consider they have a limited in the
support and management of patients with CFS/ME [6].
A recent UK multicentre clinical study randomised pri-
mary care patients to one of three treatments: pragmatic
rehabilitation (PR) or supporting listening (SL), a non-
directive counselling approach, delivered over ten sessions
by primary care nurses, or treatment as usual (TAU) [7].
PR provides an explanation for patients’ symptoms, based
on a model in which CFS occurs as a consequence of
physiological dysregulation associated with inactivity, dis-
turbance of sleep and circadian rhythms, and the somatictral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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symptoms of arousal or anxiety. The explanation provides
the rationale for a rehabilitation program, developed col-
laboratively with the patient, which includes a graded
model is presented to patients both verbally and in the
form of a fully referenced manual. The therapy aims to
help patients understand the model and to support them
as they make the behavioural and lifestyle changes sug-
gested by the model. PR was effective after 18 weeks of
treatment in reducing fatigue, depression and improving
sleep, but these effects had diminished one year later [7].
The purpose of this article is to present a cost-
effectiveness analysis to compare costs and Health Related
Quality of Life (HRQoL), as measured by quality-adjusted
life years (QALYs), associated with these treatments.Methods
Decision problem
The decision problem addressed in this paper is to
assess the cost-effectiveness of three treatment strategies
for CFS/ME, Pragmatic Rehabilitation (PR), Supportive
Listening (SL) and Treatment as Usual (TAU) delivered
by GPs in a primary care setting, in the budget con-
strained system of the UK NHS. Briefly, the clinical
study on which this cost-effectiveness analysis is based
was a three armed randomised controlled trial compar-
ing the three strategies listed above. PR, originally devel-
oped in a secondary care context [8] involves an
individualized programme of activity and improved sleep
hygiene developed collaboratively between the patient
and therapist (in this study, a primary care based nurse).
SL is a variant of a non-specific counselling intervention
originally designed for common psychological difficul-
ties, while TAU represents the treatment as usual or
management received by patients with CFS/ME from
their GP. PR and SL interventions were delivered by
three registered adult-speciality general nurses who had
worked in primary care, but had no prior experience of
CFS/ME; all three nurses delivered both pragmatic re-
habilitation and supportive listening. It was expected PR
and SL would be delivered to patients over ten sessions.
Patients aged 18 or over with CFS/ME that had been
present for over 6 months were eligible; full inclusion
and exclusion criteria are presented in the original clin-
ical paper [7].
The cost-effectiveness analysis is conducted from the
perspective of the National Health Service and personal
social services and measures costs to the NHS at 2008/
09 prices. Costs and outcomes (as measured by Quality
Adjusted Life Years) are discounted at 3.5% per year [9].
Private expenditures, the costs of informal care and the
costs of lost production are reported in a descriptive
analysis. The interventions, population and recruitmentprocedures for the study are described in detail else-
where [7].
Parameter estimates
Health related quality of life outcomes
HRQoL is measured using Quality Adjusted Life Years
(QALYs). QALYs are the product of the health state of each
individual and the time spent in that state. The health state
of each individual in the study was assessed at entry to the
trial (week 0), after treatment (week 20), and one year after
treatment (week 70) using the EQ5D instrument.
Resource use and unit costs
Patients were asked to recall use of hospital services
(inpatient, outpatient, A&E, day case surgery), day ser-
vices (day centre, drop-in centre or social club), and con-
tacts with health professionals over the time period of
the trial. In addition, detailed costing of use of all pre-
scribed medications was performed for each follow-up
[10]. The cost of delivering the intervention, in terms of
nurse time, travel and training was also included. Though
ten sessions were scheduled for each PR was delivered
over a mean of 9.5 sessions with SL delivered over a
mean of 9.6 sessions (see web appendix).
Costs of CFS/ME borne by patient or family
The trial collected data from patient questionnaires on
the economic impact of CFS/ME on patients and their
families. These costs included help from informal carers,
payments for prescription and over-the-counter medi-
cines, payment for complementary therapies, major one
off expenses, lost days and lost income from work and
days lost from leisure. These costs are described in this
paper but are not included in the estimation of the cost-
per-QALY [9].
Missing values
Missing data arose where patients did not fully complete
the follow up questionnaires, or missed one or more fol-
low up interviews. In the base case analysis missing data
were imputed by multiple imputation using chained
equations (see web appendix) [11]. Complete case ana-
lysis (excluding patient with missing data) was carried
out as a sensitivity analysis.
The questionnaire at 70 weeks post-randomization
asked about patient experience and resource use during
the previous 6 months (i.e. 26 weeks), to reduce the risk of
recall bias. Hence no resource use data were collected by
the trial between weeks 20 to 44. Therefore in all analyses
and for all patients, costs were imputed during this period
based on mean weekly health-care expenditure for that
patient during the other two follow up periods (excluding
the cost of the intervention). These imputations were
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chained equations to reflect uncertainty.Cost-effectiveness analysis
Regression analysis was used to estimate the mean differ-
ence in cost and mean difference in QALYs per patient for
each treatment over 70 weeks, relative to treatment as
usual. Incremental cost effectiveness ratios (ICERs) were
calculated where appropriate; ICERs formally compare the
incremental costs and effects associated with intervention
(s) (see web appendix). Conventionally, NHS treatments
in England are considered cost-effective by NICE if the in-
cremental cost-effectiveness ratio is less than £20,000 per
QALY [9]. For interventions that are associated with an
ICER between £20-30,000 per QALY gained, there needs
to be evidence that the intervention is innovative and/or
that HRQoL is not captured adequately and/or that there
is considerable uncertainty around the ICER. As the ICER
goes above £30,000 per QALY gained, this evidence needs
to be stronger [9].
Semi-parametric bootstrapping is used to estimate of
the probability that each intervention is cost-effective for
a range of threshold values of a QALY; cost-effectiveness
acceptability curves are used to graphically represent this
uncertainty around the adoption decision [12,13]. The
bootstrap is semi-parametric (rather than fully non-Table 1 Unit costs of health care services
Description Mean £ SD £ Source
Cost per elective bed day 290 100 Mean c
Cardiac Intensive Care Unit 1226 217 Mean c
Outpatient 109 63 Mean c
teams,
Day case procedure 854 1403 Mean c
A&E 163 105 Mean c
Day care session (am or pm) for people
with mental health problems
21 PSSRU
Physiotherapist 53 NHS Re
Occupational Therapist 62 NHS Re
District Nurse 38 PSSRU
General practitioner 35 PSSRU
Practice nurse 11 PSSRU
Phlebotomy 223 Mean c
GP home visit 117 PSSRU
Nurse specialist (community) 89 PSSRU
Travel 1.4 PSSRU
Medication various BNF (58
Home help (used to estímate
opportunity cost of informal care)
14 PSSRU
Private expenditures Various Valued
Lost income from work Various Valued
_* updated to 2008/2009 prices by NHS pay and prices inflation factor (PSSRU).parametric) because at each resample the model esti-
mates parametric regressions to impute missing data,
thereby imposing some parametric constraints on the
predictions of incremental costs and QALYs and their
distributions [14].
Table 1 shows the unit costs for each resource cap-
tured in the trial.
Results
Costs of healthcare
Table 2 shows the mean costs of each type of healthcare
service at each follow up period Resource use is shown
in the web appendix.
Figure 1 summarises the mean undiscounted costs per
patient by randomised treatment group for patients who
were followed up at both week 20 and week 70. Costs
are imputed from week 20 to week 44 based on mean
resource use in the other follow up periods, as no data
were collected in the trial for this period. Supportive
listening tended to be more costly over the whole trial
period but there was not a statistically significant differ-
ence in total cost per patient between groups (p= 0.33).
Economic impact of CFE/ME on patient and family
Though outside the strict perspective of the NHS and per-
sonal social services advocated by NICE [9], the economicost per elective bed day 2007/8 across all specialities* [15]
ost per day 2007/8* [15]
ost per visit 2007/8 excluding haemotology, cancer multidisciplinary
cystic fybrosis, HIV, transplant and paediatrics* [15]
ost per day case procedure 2007/08* [15]
ost 2007/08 of A&E attendances [15]
[16]
ference costs 2007/8* [15]
ference costs 2007/8* [15]
[16]
[16]
[16]
ost vascular surgery outpatient multiprofessional face to face 2007/8* [15]
[16], 23.4 min consultation including travel
[16], per hour of contact time
[16], per visit
) 2009 [10]
[16] (Community care package low cost, prívate home care), per hour
by patient in questionnaires
by patient in questionnaires
Table 2 Cost of health care services and non-NHS expenditures related to CFS/ME at each follow up, by treatment
group (mean, sd)*
Week 0 to 20 Week 44 to 70
Pragmatic
rehabilitation
Supportive
listening
Treatment as
usual
Pragmatic
rehabilitation
Supportive
listening
Treatment as
usual
NHS costs of CFS/ME Mean £,
N=85
sd Mean £,
N=97
sd Mean £,
N=92
sd Mean £,
N=81
sd mean £,
N=90
sd Mean £,
N=86
sd
Inpatient 7 (63) 84 (345) 63 (357) 54 (367) 93 (512) 34 (144)
Outpatient 126 (239) 192 (415) 199 (460) 210 (388) 213 (437) 174 (246)
Accident & Emergency 17 (56) 24 (67) 11 (40) 10 (47) 16 (49) 19 (63)
Daycase surgery 10 (93) 18 (122) 56 (212) 63 (225) 104 (309) 50 (201)
Day facility 15 (104) 3 (14) 21 (151) 13 (82) 6 (42) 0 (0)
General practicioner
(GP)
89 (118) 112 (142) 129 (169) 218 (1142) 157 (252) 158 (308)
GP home visit 12 (57) 7 (44) 5 (24) 12 (80) 13 (75) 5 (50)
Practice nurse 1 (5) 2 (7) 8 (32) 2 (8) 6 (15) 7 (27)
Occupational therapy 10 (52) 6 (35) 1 (6) 0 (0) 4 (28) 0 (0)
District nurse 0 (0) 4 (39) 0 (0) 0 (0) 0 (0) 0 (0)
Physiotherapy 4 (26) 16 (112) 3 (28) 0 (0) 1 (8) 10 (76)
Phlebotomy 76 (208) 51 (127) 90 (252) 77 (194) 109 (237) 130 (238)
Medications 99 (171) 138 (182) 143 (246) 127 (245) 194 (293) 117 (171)
Total NHS cost of CFS/
ME during the follow
up period (excluding
PR/SL intervention)
468 (639) 655 (750) 739 (974) 789 (1390) 916 (1156) 710 (814)
Mean cost per person
per week of CFS/ME
to NHS (excluding PR/
SL intervention)
23 33 37 30 35 27
Cost of pragmatic
rehabilitation and
supportive listening
interventions
577 (219) 517 (224) 0 (0) 0 (0) 0 (0) 0 (0)
Non-NHS costs of CFS/
ME
Informal care (**) 2096 (4172) 3538 (6016) 2426 (3791) 2816 (4311) 2339 (3930) 3102 (4221)
Private expenditure 145 (306) 1343 (11086) 260 (452) 455 (1367) 321 (894) 315 (932)
Lost earnings 2601 (6460) 4661 (15215) 3450 (7459) 5562 (8776) 3494 (8509) 3321 (5285)
*product of unit cost and resource use. Thus relevant resource use is obtained by dividing number in table 2 by relevant number in Table 1.
** Informal care has been costed at an hourly rate equivalent to a home help. PR Pragmatic rehabilitation SL Supportive Listening.
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of interest to decision makers (see web appendix). Non-
parametric K-sample tests of differences in medians be-
tween the groups found a difference at the 5% significance
level for major one off expenses at week 20 and lost leisure
time at week 70. However, after adjustment for multiple
comparisons, ANOVA tests found that mean expenditures
did not differ significantly by treatment group at week 70,
controlling for health expenditure by individuals in the 6
months before the start of the trial. However, there is some
weak evidence that those in the treatment as usual arm had
greater loss of leisure time and higher costs of informal care
than those in the PR group (Table 2).Health related quality of life
Table 3 shows the proportion of patients in each health
state of the EQ5D for 296 patients at baseline, 274
patients who were interviewed at week 20 and the 257
patients who were interviewed at week 70.
Figure 2 shows mean EQ5D index at baseline, week 20
and week 70 by randomised group (without multiple im-
putation). HRQL tended to increase in all groups at
week 20 but returned towards baseline levels by week
70. ANOVA found that the differences in HRQL bet-
ween treatment groups (adjusted for baseline EQ5D)
were not statistically significant (p=0.47 at week 20 and
p=0.75 at week 70).
Table 3 Percentage of patients in each EQ5D dimension by group at baseline and follow-up
Pragmatic rehabilitation
% of patients in health state at
baseline, N=95
% of patients in health state at week
20 N=85
% of patients in health state at week
70 N=81
1 2 3 1 2 3 1 2 3
Mobility 33.7 64.2 1.0 44.7 55.3 0.0 54.3 44.4 1.2
Self-care 63.2 35.8 1.0 78.8 20.0 1.2 67.9 30.9 1.2
Usual activities 7.4 62.1 30.5 21.2 65.9 12.9 23.5 56.8 19.8
Pain / discomfort 11.6 66.3 21.1 19.1 60.7 20.2 14.8 67.9 17.3
Anxiety / depression 46.3 46.3 7.4 55.3 41.2 3.5 45.7 46.9 7.4
Supportive listening
% of patients in health state at
baseline N=101
% of patients in health state at week
20 N=97
% of patients in health state at week
70 N=90
1 2 3 1 2 3 1 2 3
Mobility 18.8 80.2 1.0 33.0 66.0 1.0 32.2 65.6 2.2
Self-care 56.4 39.6 3.0 63.9 35.1 1.0 60.0 36.7 2.2
Usual activities 4.0 69.3 25.7 11.3 64.9 23.7 12.2 71.1 16.7
Pain / discomfort 11.9 71.3 16.8 16.5 63.9 19.6 14.4 67.9 17.3
Anxiety / depression 42.6 47.5 9.9 46.4 50.5 3.1 45.6 48.9 5.6
Treatment as usual
% of patients in health state at
baseline N=100
% of patients in health state at week
20 N=92
% of patients in health state at week
70 N=86
1 2 3 1 2 3 1 2 3
Mobility 30.0 69.0 1.0 48.9 51.1 0.0 37.2 60.5 2.3
Self-care 65.0 34.0 1.0 66.3 32.6 1.1 65.1 33.7 1.2
Usual activities 13.0 52.0 35.0 17.4 64.1 18.5 15.1 76.7 8.1
Pain / discomfort 14.0 60.0 26.0 13.1 69.2 17.6 11.6 66.3 22.1
Anxiety / depression 53.0 36.0 10.0 65.9 27.5 6.6 55.8 38.4 5.8
1=no problems, 2= some/moderate problems, 3=extreme problems.
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Figure 1 Mean costs per patient accrued during the trial by treatment (n=254).
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Figure 2 Changes in EQ5D index over time by treatment group.
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Of the 296 participants in the trial, 254 were followed
up at week 20 and week 70, 19 were not followed up at
either week 20 or week 70, 20 were followed up at week
20 only, and 3 were followed up at week 70 only. There
were no statistically significant differences in the prob-
ability of follow up between randomised groups. Mul-
tiple imputation was used to impute missing data (costs
and EQ5D) (The Additional file 1: web appendix gives
details of validation for the imputation procedures).
Cost-effectiveness analysis
Table 4 shows mean incremental QALYs and mean in-
cremental costs compared with treatment as usual. Mul-
tiple imputation has been used to deal with missing
data, and confidence intervals have been estimated by
bootstrapping the 15 imputed datasets. After adjusting
for baseline differences in EQ-5D, TAU delivered in pri-
mary care tends to be slightly more effective than either
PR or SL and at a lower cost. Estimates of both incre-
mental costs and effects are associated with considerable
uncertainty with all confidence intervals crossing zero.Table 4 Results of cost-effectiveness analysis, after adjusting
Mean incremental QALY (compared with treatm
N = 296, with imputation of missing data in 23 patients who were followed up
Pragmatic rehabilitation −0.012
Supportive listening −0.042
N=254, without imputation (complete cases )
Pragmatic rehabilitation 0.012
Supportive listening −0.039Given that on average TAU has lower costs and better
outcomes that either intervention, it is the dominant
therapy and calculation of an ICER is not appropriate
[17]. However, there is a considerable amount of uncer-
tainty around these estimates. The probability that TAU
is cost-effective is 0.645 at a threshold cost-per-QALY of
£20,000, 0.626 at a threshold of £30,000 per QALY and
0.600 at a threshold of £50,000 (Figure 3).
Sensitivity analysis
A complete case analysis (N=254) (excluding patients
who did not complete questionnaires at baseline, 20
weeks or 70 weeks), suggested that PR tended to be
associated with slightly higher QALYs than TAU though
again with wide confidence intervals that crossed zero
(Table 4). In this analysis, PR has an incremental cost-
effectiveness ratio of £39583 per QALY versus TAU (cal-
culated as £475/0.012). SL is dominated by TAU. Based
on this sensitivity analysis, TAU is likely to be the pre-
ferred option as the ICER associated with PR is higher
than that usually recommended [9]. Pragmatic rehabili-
tation and treatment as usual were roughly equally likely
to be cost effective at a threshold of £30000 per QALY
in the complete case analysis (Figure 3).
Discussion
Summary of main findings
This study has compared the costs and QALYs of prag-
matic rehabilitation versus supportive listening versus GP
delivered treatment as usual for patients with CFS/ME
treated in the community. Supportive Listening was no
more effective than the other therapies and more costly,
and is therefore not cost-effective. The primary analysis
(imputing for missing data) also finds that Pragmatic
Rehabilitation (PR) does not appear to be more effective
than GP delivered treatment as usual over the time scale
of the study, and does not appear to be cost-effective. A
secondary analysis (using complete cases only) found that
PR tended to be slightly more effective than treatment
as usual. In this analysis which favours PR, the
cost-per-QALY generated compared with treatment as
usual is greater than £30000 per QALY and pragmaticfor differences in baseline EQ5D
ent as usual) 95%
confidence
interval
Mean incremental
cost (compared with
treatment as usual)
95%
confidence
interval
at only one time point and 19 patients who only had baseline data
−0.088 0.065 218 −474 911
−0.122 0.038 460 −250 1169
−0.076 0.101 475 −29 980
−0.125 0.047 698 210 1186
0
.
2
.
4
.
6
.
8
0 20000 40000 60000 80000 100000
Threshold cost-per-QALY (pounds)
Pragmatic rehabilitation Supportive listening
Treatment as usual
Figure 3 Cost-effectiveness acceptability curve.
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current thresholds used in the UK. Whether these thresh-
olds are appropriate in the UK for this patient popula-
tion is open to debate. Some authors have suggested
that the thresholds may be too high [18], while others
have suggested that the public may value a QALY at
over £30,000 [19].
The findings of this analysis are broadly consistent
with the clinical study of this trial, which concluded that
the benefits of pragmatic rehabilitation seen while treat-
ment was ongoing attenuated over the one year follow
up period [7]. It is worth noting that the clinical effect-
iveness of PR delivered in primary care as reported by
Wearden et al. [7] was much less than in a previous trial
of PR in secondary care [8]. The conclusion from this
single trial analysis is that whether there are benefits
associated with PR when delivered in this way depends
on the analysis chosen. However, any increases in
QALYs generated by PR are not substantial and GP
delivered TAU is likely to be cost-effective.
Strengths and limitations
The current study finds that although pragmatic re-
habilitation delivered in primary care appears to be asso-
ciated with benefits to patients at 20 weeks, patients also
improve on average in the GP delivered treatment as
usual arm. The incremental benefit of PR, as measured
by QALYs over the time period of the trial, is very small
or non-existent. The current study has a time horizon of
70 weeks. This in effect assumes there are no differences
between treatments one year after the end of the trial
therapy period. While the assumption potentially may be
a source of bias, in this case it is probably justified given
that the mean HRQoL of all groups appears to convergeat 70 weeks. As with all evaluations that use patient
assessments of their health status and resource use at spe-
cified time points, we do not know the extent of over/
under-estimation. In addition we do not know the trajec-
tory of the EQ5D scores over the whole time period. We
have assumed a linear interpolation of EQ5D scores, but
while this is common practice, the small absolute differ-
ences in effect size suggest that any variation from this
may have had an impact on results and conclusions.
The perspective of the study covers health and per-
sonal social services. However, the presentation of ques-
tions in the patient questionnaire may mean that some
social care use was under-reported. Some services, such
as family support workers and other social care costs
were not explicitly included, but are unlikely to influence
the conclusions. The inclusion of productivity losses is
also unlikely to influence conclusions.
In addition, the study only considers three options.
There may be other ways of designing services so that, for
example, PR could be delivered less expensively, perhaps
by practice nurses or GPs could be better trained to recog-
nise and manage CFS/ME [20]. In addition, we know that
patients needed to believe in the intervention model pre-
sented in order to engage fully [21]. Ideally these options
should be considered as part of the evaluation.
Comparison with existing literature
A recently published trial [22] suggests that graded ex-
ercise therapy leads to better patient outcomes (in terms
of reduced fatigue and better physical function) than
standardised usual specialist medical care. The cost-
effectiveness analysis conducted alongside this trial [23]
showed that both graded exercise therapy (GET) and Cog-
nitive Behavioural Therapy (CBT) added significantly
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life when compared with specialised medical care
(SMC). The authors conclude that GET was likely to
be cost-effective when compared to SMC, but that
CBT had the highest probability of being cost-effect-
ive. However, like the patients in the previous PR trial
reported by Powell et al. (2001) [8], these patients
had been referred to secondary care and so were a
selected group, unlike the group in the FINE trial.
The results of the present analysis can be compared
with a previous study that estimated the economic bur-
den of CFS/ME in a UK primary care setting 2003 [3].
The costs of health services seem slightly higher in the
current study, and the costs of informal care appear con-
siderably lower in the current study. However, these
differences may be due to recall bias or due the wording
of the study questionnaires, rather than reflecting real
differences.
Implications for future research and clinical practice
There is a body of evidence that suggests that patients
with CFS/ME are not satisfied with the care they cur-
rently receive from primary care, and that GPs find man-
agement of these patients difficult [5,21]. Thus the
suggestion that the cost-effective solution should be
implemented is of limited use if patients feel that this
option is not acceptable. Thus further research into ef-
fective management options for patients with CFS/ME is
needed. In addition, the skills of GPs in making the diag-
nosis of CFS/ME and offering acceptable treatment, or
referral to specialist CFS/ME services, need to improve.
The team are currently developing and evaluating resources
to support GPs and patients with CFS/ME.
Conclusions
Clinical commissioning groups will need to consider
what are the appropriate services to commission for
patients with CFS/ME and where they should be pro-
vided and cost-effectiveness might not be the only
consideration.
Additional file
Additional file 1: An economic evaluation alongside a randomised
controlled trial of a nurse-led home-based self-help treatment for
patients in primary care with chronic fatigue syndrome.
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